Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program

BACKGROUND: Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of gastrointestinal stromal tumors (GIST) although most patients develop resistance to first and second-line therapies. Regorafenib, an oral multi-targeted TKI, has demonstrated benefit in previously treated GIST patients...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Sarcoma Res
Glavni autori: Kollàr, Attila, Maruzzo, Marco, Messiou, Christina, Cartwright, Elisabeth, Miah, Aisha, Martin-Liberal, Juan, Thway, Khin, McGrath, Ellen, Dunlop, Alison, Khabra, Komel, Seddon, Beatrice, Dileo, Palma, Linch, Mark, Judson, Ian, Benson, Charlotte
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4405914/
https://ncbi.nlm.nih.gov/pubmed/25905001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-3329-4-17
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items